Arrowstreet Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Arrowstreet Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,234	Closed	-$418K	–	1496
2022 Q2	$418K	Buy	+6,234	New	+$396K	﹤0.01%	1089
2021 Q2	–	Sell	-52,900	Closed	-$9.06M	–	2312
2021 Q1	$9.06M	Sell	52,900 -70,650	-57%	-$14M	0.01%	926
2020 Q4	$27.1M	Buy	+123,550	New	+$26.7M	0.04%	489
2019 Q4	–	Sell	-13,715	Closed	-$1.07M	–	1956
2019 Q3	$1.07M	Buy	+13,715	New	+$1.29M	﹤0.01%	1145

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Arrowstreet Capital's MRTX Position: Q3 2022 in Review

Arrowstreet Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 6,234 shares — an estimated $418K sold.

Arrowstreet Capital first reported a position in MRTX in Q3 2019 and held it in 4 quarters. The position peaked at $27.1M in Q4 2020. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Arrowstreet Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Arrowstreet Capital sold 6,234 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $418K.
Arrowstreet Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
Arrowstreet Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $27.1M in Q4 2020.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.